Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.

Circulation. 2017 Jan 24;135(4):352-362. doi: 10.1161/CIRCULATIONAHA.116.025253. Epub 2016 Dec 16.

2.

Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.

Reyes-Soffer G, Moon B, Hernandez-Ono A, Dionizovik-Dimanovski M, Jimenez J, Obunike J, Thomas T, Ngai C, Fontanez N, Donovan DS, Karmally W, Holleran S, Ramakrishnan R, Mittleman RS, Ginsberg HN.

Sci Transl Med. 2016 Jan 27;8(323):323ra12. doi: 10.1126/scitranslmed.aad2195. Erratum in: Sci Transl Med. 2016 Feb 10;8(325):325er3. Dionizovick-Dimanovski, Marija [corrected to Dionizovik-Dimanovski, Marija].

3.

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN.

J Clin Invest. 2005 May;115(5):1323-32. Epub 2005 Apr 1.

4.

HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects.

Berglund L, Oliver EH, Fontanez N, Holleran S, Matthews K, Roheim PS, Ginsberg HN, Ramakrishnan R, Lefevre M.

Am J Clin Nutr. 1999 Dec;70(6):992-1000.

PMID:
10584043

Supplemental Content

Loading ...
Support Center